# DESCRIPTION

## INTRODUCTION

- motivate CD47 antibodies

## SUMMARY

- introduce compositions and methods
- specify anti-CD47 antibody
- outline treatment methods

## DESCRIPTION

- provide headings and disclaimer

### Definitions

- define technical terms
- describe conventional procedures
- cite references
- define singular and plural terms
- explain use of "and/or"
- define "comprising", "including", and "having"
- define "about" and "approximately"
- define "peptide", "polypeptide", and "protein"
- define "nucleic acid", "nucleic acid molecule", and "polynucleotide"
- define "recover" and "recovery"
- define "isolated"

### MEWS WVFLFFLSVTTGVHS (SEQ ID NO:40).

- define antigen-binding protein
- describe structure of antigen-binding protein
- introduce immunoglobulin
- describe structure of immunoglobulin
- explain variable regions of immunoglobulin chains
- describe CDRs and their role in antigen binding
- introduce antibody and related terms
- describe antigen binding portions of antibodies
- introduce monoclonal antibody
- describe production of monoclonal antibodies
- define antigen binding domain
- explain specific binding of antibodies
- describe measurement of binding affinity
- introduce epitope
- describe antagonist and agonist antibodies
- introduce antibody fragments
- describe Fab, F(ab')2, Fv, and other antibody fragments
- introduce humanized and fully human antibodies
- describe production of humanized and fully human antibodies
- define chimeric antibody
- describe framework regions of chimeric antibody
- define variant polypeptides and polynucleotides
- define derivative of polypeptide
- define antibody
- define hinge region
- describe Fc region
- define labeled polypeptide
- define percent identity and percent homology
- describe similarity between test antibody and anti-CD47 antibodies
- define vector
- describe expression vector
- define transgene
- define operably linked
- define transfected, transformed, or transduced
- define host cell
- describe production host cell
- define subject
- define administering
- describe routes of administration
- define effective amount
- describe therapeutically effective amount

### Antibody Combination

- introduce antibody composition
- describe anti-CD47 antibody
- specify heavy chain variable region
- specify light chain variable region
- describe alternative anti-CD47 antibodies
- describe tumor antigen-binding antibody
- specify examples of tumor antigens
- describe production of polypeptides
- describe expression vector construct
- describe host cells for production
- describe purification methods

### Pharmaceutical Compositions

- introduce pharmaceutical compositions
- describe anti-CD47 antibody in composition
- describe tumor antigen-binding antibody in composition
- describe excipients and formulation
- describe parenteral administration
- describe kit composition and use

### Methods of Treatment

- define disease/disorder associated with tumor-associated antigens
- specify types of cancer and tumor cells
- describe method of treatment using CD47 antibody and tumor targeting antibody
- outline synergistic effects of combination therapy
- discuss reduced toxicity of CD47 antibody treatment
- describe oral delivery formulations
- outline parenteral administration routes and formulations

## EXAMPLES

- present multiple examples of STI-6643 antibody

### Example 1. STI-6643 Demonstrates Drastically Reduced Hemagglutination as Compared to Competitor Antibody Hu5F9

- prepare red blood cells
- perform hemagglutination assay

### Example 2. STI-6643 Blocks Human CD47/SIRPα Interaction in a Dose-Dependent Manner

- perform CD47/SIRPα interaction assay

### Example 3. STI-6643 Promotes Phagocytosis of Tumor Cells in a Dose-Dependent Manner

- prepare tumor cells and antibodies
- perform ADCP assay

### Example 4. STI-6643 Improves Rituximab-induced Phagocytosis When Combined at Suboptimal Doses

- prepare macrophages and tumor cells
- perform ADCP assay with Rituximab and STI-6643

### Example 5. STI-6643 Shows Comparable Anti-Tumor Activity Than Hu5F9 in a Preclinical Mouse Model

- perform anti-tumor activity assay in mouse model

### Example 6. Combination of STI-6643 and Rituximab Improves Anti-Tumor Activity and Prolonged Survival

- perform combination therapy in mouse model

### Example 7. STI-6643 is Well Tolerated and Safe in Non-Human Primates at 150 mg/kg

- perform toxicity study in cynomolgus monkeys
- evaluate hemoglobin levels over time

### Example 8. Anti-CD47 Clone STI-6643 Shows Preferential Binding to Tumor Cells. Binding Assay on Mixed-Cell Samples

- perform binding assay on mixed-cell samples

### Example 9. STI-6643 Drastically Reduces Hemagglutination as Compared to Competitor Antibody Hu5F9 (Additional Hemagglutination Experiment)

- prepare red blood cells
- perform hemagglutination assay
- add antibodies to RBCs
- incubate plate
- observe results
- provide diagram of results
- show results of assay
- conclude STI-6643 does not induce hemagglutination
- introduce Example 10
- prepare PBMCs
- perform 3-way MLR assay
- analyze results
- conclude STI-6643 preserves immune system
- describe experimental design
- administer antibodies and measure tumor growth
- calculate tumor growth inhibition
- plot Kaplan-Meier survival curves
- perform hemagglutination assay
- prepare red blood cells
- test antibody binding to red blood cells
- analyze binding results
- perform binding assay with Raji cells
- analyze binding results to Raji cells
- incubate PBMCs with anti-CD47 antibodies
- stain for immune cell markers
- analyze immune cell recovery
- perform efficacy study in humanized mouse model

